Stemnovate has the world’s first commercial biobank for human iPS cells with complete genotype information. We pride ourselves in supplying high quality cells but that’s not all we offer. Our research and development technology can save precious time and cost ensuring success and our partnerships with top tier pharmaceutical companies and world’s top research institutes allows for new technologies and applications development at a pace not imagined before.

Compliant & Ethical biobanking

Through commercial brokers, cells could be coming from anywhere - In a recent survey, the Medicines Discovery Catapult found that diagnostics small and medium enterprises (SMEs) in the UK obtained 75% of their samples from other countries where there is less concern around the ethics of the trade of human tissues. At Stemnovate, we source all our cells from living donors with complete informed consent, the ethical concerns around biobanking are important to us and we are dedicated to having a high-quality ethical biobank. We hold a Human Tissue Act License and follow compliance and regulations in the UK

alt

Quality Assured

With Stemnovate you can be sure of the quality of our cells, we have a dedicated team growing and testing our cells and all cells will have tested negative for HIV-1, HIV-2, Hepatitis-A, Hepatitis-B, bacteria, and mycoplasma. Our cells are cultured in defined conditions and are profiled for cell growth and the expression of key biomarkers. We also offer profiling and bioinformatics to analyse the cells and offer more information, such as genotype information for major drug-metabolizing enzymes such as Cytochrome P450.

alt

Gender & Ethnic Diversity

According to a 2001 article by Margaret Ann Miller from the Office of women’s health (OWH), Food and Drug Administration (FDA), women experience more adverse reactions to treatment with therapeutic drugs than men because of differences in drug metabolism. Stemnovate biobank addresses the lack of gender diversity with a robust collection of female primary cells and induced pluripotent stem cell lines. Using cells from a more diverse sample selection can help to see the differences in drug metabolism and individual variability in clinical response.

Reducing Animal Testing

In 2020, 2.88 million procedures were carried out in Great Britain involving living animals (Annual Statistics of Scientific Procedures on Living Animals, Great Britain, 2020), we are committed to helping contribute to reducing this: Since the start of our company in 2016, we have not sacrificed any animals and built alternative technologies for human and animal studies. Our work helps to make alternative drug models to animal models using our high-quality cells. By using cell cultures to investigate the drug activity, metabolism, and toxicity of any possible drug candidates you can establish if the compound is viable for further development without the use of live animals. This reduces the number of non-viable drugs used in further animal studies, reducing animal testing and its associated costs.